Insmed (INSM) Earnings Date & Reports

Key Takeaways

• Q2 2026 results are expected on or around August 6, 2026, before market open. Consensus estimates point to revenue of approximately $391 million and an EPS (earnings per share) loss of roughly $0.75.
• BRINSUPRI (brensocatib) sales trajectory is the single most important metric. After delivering $207.9 million in Q1 with 44% sequential growth, investors want to see continued patient adoption and whether the $1 billion full-year guidance remains firmly on track.
• Headwinds from recent pipeline setbacks are still weighing on sentiment. The failures of the Phase 2b CEDAR and BiRCh studies earlier in 2026 have narrowed BRINSUPRI's expansion potential and contributed to the stock's roughly 40% year-to-date decline.
• ARIKAYCE and the ENCORE catalyst add a secondary layer of interest. Positive Phase 3b ENCORE data announced in Q1 sets up a potential label expansion filing in the second half of 2026, which could meaningfully broaden ARIKAYCE's addressable market.
• Cash runway and expense discipline remain critical. With approximately $1.2 billion in cash and marketable securities at the end of Q1, management has reiterated a path to cash-flow positivity by 2027 without additional capital.

Earnings Context and Why It Matters

Insmed's second-quarter 2026 earnings report lands at a pivotal moment for the company. BRINSUPRI, launched in the U.S. in August 2025 for non-cystic fibrosis bronchiectasis, is in the early innings of what management projects as a blockbuster commercial opportunity — with full-year revenue guidance of at least $1 billion. This quarter will test whether the launch trajectory can sustain its early momentum after two consecutive pipeline failures in hidradenitis suppurativa and chronic rhinosinusitis rattled investor confidence. With the stock trading near $101, well below its 52-week high of $212.75, the report represents a critical checkpoint for the growth narrative that underpins the bull case.

Earnings Expectations

Analysts expect Insmed to report Q2 2026 revenue of approximately $391 million, which would represent roughly 264% growth from the $107.4 million reported in Q2 2025. The consensus EPS estimate stands at a loss of approximately $0.75 per share, a substantial improvement from the $1.70 loss per share in the year-ago period. These expectations reflect the transformative impact of BRINSUPRI's commercial launch, which contributed $207.9 million in revenue in Q1 2026 alone — more than double total company revenue in Q1 2025.

Key metrics investors will scrutinize include: BRINSUPRI new patient starts (which reached approximately 7,800 in Q1), gross-to-net pricing dynamics (guided at mid-20s to low-30s percentage range), continuation rates, and prescriber base expansion. On the ARIKAYCE side, the company guided full-year revenue of $450 million to $470 million. Operating expenses — particularly R&D (research and development) and SG&A (selling, general and administrative expenses) — will be closely watched after Q1 spending of $209.5 million and $247.3 million, respectively. Historically, Insmed shares have exhibited significant post-earnings volatility; following Q1 results, the stock dropped approximately 14% in pre-market trading despite beating both EPS and revenue expectations.

AI Screener

For investors seeking to stay ahead of market-moving events like Insmed's upcoming earnings report, Tickeron's AI Screener offers a sophisticated AI-powered stock and ETF (exchange-traded fund) discovery platform. The tool allows traders and investors to filter thousands of equities using customizable criteria including industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-driven signals. Whether scanning for breakout candidates, trending sectors, or stocks exhibiting specific fundamental and technical profiles, the AI Screener streamlines the discovery process and surfaces trade ideas more efficiently than manual screening. Explore the AI Screener to complement your earnings season research with data-driven market intelligence.

Market Reaction and Investor Sentiment

Sentiment heading into Q2 earnings is cautiously defensive. INSM shares have declined sharply from their December 2025 peak of $212.75, pressured by a combination of pipeline disappointments and broader biotech sector weakness. The failed CEDAR and BiRCh studies eliminated two potential expansion indications for brensocatib, compressing the long-term revenue narrative. While the core bronchiectasis opportunity remains intact, the market is demanding proof that BRINSUPRI's commercial ramp can continue at a pace that justifies the company's elevated expense base and ~$22 billion market capitalization. Options market activity and recent trading patterns suggest investors are bracing for a potentially wide post-earnings swing. The stock's reaction to Q1 results — a double-digit decline despite a headline beat — underscores that the bar for a positive surprise may be higher than headline consensus numbers alone suggest.

Forward Outlook and Key Factors to Monitor

Beyond Q2, several developments will shape Insmed's trajectory through the remainder of 2026. The most significant near-term catalyst is the ENCORE study follow-through. With positive topline data already in hand, management plans to submit a supplemental New Drug Application (sNDA) for ARIKAYCE in the U.S. and a corresponding filing in Japan during the second half of 2026. If approved, the label expansion could increase ARIKAYCE's addressable patient population from roughly 30,000 to over 200,000, representing a substantial commercial opportunity.

On the pipeline front, TPIP (treprostinil palmitil inhalation powder) is advancing through four Phase 3 programs, including PALM-PAH in pulmonary arterial hypertension. Open-label extension data from the PAH program is expected in Q3 2026, offering a potential inflection point for the second major pipeline asset. Operationally, investors should monitor whether BRINSUPRI's new patient starts can sustain the 6,000-plus quarterly pace needed to hit the $1 billion target, and whether gross-to-net trends remain within the guided range. Expense management will also be in focus, as R&D and SG&A spending levels directly influence the timeline to cash-flow positivity, which management targets for 2027. With approximately $1.2 billion in cash, Insmed has ample runway, but the pace of commercial revenue growth in the coming quarters will determine whether the company can reach breakeven without dilutive financing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations